Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345547 | 1.00 | BTN3A1 (0.33) | BTN3A1DUT | |
| SCHEMBL8849600 | 0.95 | BTN3A1 (0.34) | BTN3A1DUT | |
| SCHEMBL8947094 | 0.95 | BTN3A1 (0.34) | BTN3A1DUT | |
| SCHEMBL15975343 | 0.84 | DUT (0.34) | DUT | |
| SCHEMBL31399585 | 0.83 | DUT (0.33) | DUT | |
| SCHEMBL31399609 | 0.83 | DUT (0.33) | DUT | |
| SCHEMBL26628151 | 0.82 | DUT (0.31) | DUT | |
| SCHEMBL8620154 | 0.80 | DUT (0.32) | DUT | |
| SCHEMBL8620159 | 0.80 | DUT (0.32) | DUT | |
| SCHEMBL1691509 | 0.79 | BTN3A1 (0.35) | BTN3A1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612213-B2 | (E)-ethyl 7-hydroxy-2-methyl-2-heptenate; (3E, 5E)-tert-butyl-9-(tert-butyldimethylsiloxy)-2-[(E)-ethylid ene]-4-methylnona-3,5-dienate | RIKEN (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050209463-A1 | Novel compound having antitumor activity and process for producing the same | RIKEN (JP) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209463-A1 | Novel compound having antitumor activity and process for producing the same | MCL1, MYC, HCCS | BTN3A1 4119/4885DUT 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.